95 related articles for article (PubMed ID: 22450752)
41. CD44+ and CD133+ Non-Small Cell Lung Cancer Cells Exhibit DNA Damage Response Pathways and Dormant Polyploid Giant Cancer Cell Enrichment Relating to Their p53 Status.
Pustovalova M; Blokhina T; Alhaddad L; Chigasova A; Chuprov-Netochin R; Veviorskiy A; Filkov G; Osipov AN; Leonov S
Int J Mol Sci; 2022 Apr; 23(9):. PubMed ID: 35563313
[TBL] [Abstract][Full Text] [Related]
42. Regulation of chemosensitivity and migration by clusterin in non-small cell lung cancer cells.
Cheng CY; Cherng SH; Wu WJ; Yang TY; Huang XY; Liao FT; Wu MF; Sheu GT
Cancer Chemother Pharmacol; 2012 Jan; 69(1):145-54. PubMed ID: 21630085
[TBL] [Abstract][Full Text] [Related]
43. Evaluating the immunoproteasome as a potential therapeutic target in cisplatin-resistant small cell and non-small cell lung cancer.
Shoji T; Kikuchi E; Kikuchi J; Takashima Y; Furuta M; Takahashi H; Tsuji K; Maeda M; Kinoshita I; Dosaka-Akita H; Sakakibara-Konishi J; Konno S
Cancer Chemother Pharmacol; 2020 May; 85(5):843-853. PubMed ID: 32232513
[TBL] [Abstract][Full Text] [Related]
44. Δ133p53 decreases the chemosensitivity of carcinoma cell line H1299.
Liu K; Lin J
Cell Biol Int; 2019 Aug; 43(8):960-964. PubMed ID: 31115944
[TBL] [Abstract][Full Text] [Related]
45. [Effect of inhibiting the expression of hSMG-1 on chemosensitivity of human non-small cell lung cancer H1299 cells].
Xia QS; Li YZ; Li HY; Liu X; Xu B; Xiang Q; Yu CY; Chen ZH
Zhonghua Yi Xue Za Zhi; 2011 Mar; 91(8):554-9. PubMed ID: 21418860
[TBL] [Abstract][Full Text] [Related]
46. Enhanced toxicity of cisplatin with chemosensitizer phenethyl isothiocyanate toward non-small cell lung cancer cells when delivered in liposomal nanoparticles.
Yang YT; Shi Y; Jay M; Di Pasqua AJ
Chem Res Toxicol; 2014 Jun; 27(6):946-8. PubMed ID: 24836554
[TBL] [Abstract][Full Text] [Related]
47. Emergence of higher levels of invasive and metastatic properties in the drug resistant cancer cell lines after the repeated administration of cisplatin in tumor-bearing mice.
Mitsumoto M; Kamura T; Kobayashi H; Sonoda T; Kaku T; Nakano H
J Cancer Res Clin Oncol; 1998; 124(11):607-14. PubMed ID: 9860289
[TBL] [Abstract][Full Text] [Related]
48. [Effects of cyclooxygenase-2 antisense vector on proliferation and sensitivity to cisplatin of H1299 cells].
Gao Z; Tang L; Su B; Zhao Y; Zhou C
Zhongguo Fei Ai Za Zhi; 2005 Oct; 8(5):424-7. PubMed ID: 21205525
[TBL] [Abstract][Full Text] [Related]
49. Apigenin Enhanced Antitumor Effect of Cisplatin in Lung Cancer via Inhibition of Cancer Stem Cells.
Li Y; Chen X; He W; Xia S; Jiang X; Li X; Bai J; Li N; Chen L; Yang B
Nutr Cancer; 2021; 73(8):1489-1497. PubMed ID: 32757802
[TBL] [Abstract][Full Text] [Related]
50. Amygdalin-mediated inhibition of non-small cell lung cancer cell invasion in vitro.
Qian L; Xie B; Wang Y; Qian J
Int J Clin Exp Pathol; 2015; 8(5):5363-70. PubMed ID: 26191238
[TBL] [Abstract][Full Text] [Related]
51. Synergism Effect of Dendrobine on Cisplatin in Treatment of H1299 by Modulating the Balance of Treg/Th17.
Luo Y; Liu G; Hou P
Anticancer Agents Med Chem; 2023; 23(1):105-112. PubMed ID: 35619309
[TBL] [Abstract][Full Text] [Related]
52. Small cell and non small cell lung cancer form metastasis on cellular 4D lung model.
Mishra DK; Miller RA; Pence KA; Kim MP
BMC Cancer; 2018 Apr; 18(1):441. PubMed ID: 29669530
[TBL] [Abstract][Full Text] [Related]
53. A Theoretical Model for the Hormetic Dose-response Curve for Anticancer Agents.
Yoshimasu T; Ohashi T; Oura S; Kokawa Y; Kawago M; Hirai Y; Miyasaka M; Nishiguchi H; Kawashima S; Yata Y; Honda M; Fujimoto T; Okamura Y
Anticancer Res; 2015 Nov; 35(11):5851-5. PubMed ID: 26504007
[TBL] [Abstract][Full Text] [Related]
54. Influence of methotrexate and cisplatin on tumor progression and survival in the VM mouse model of systemic metastatic cancer.
Huysentruyt LC; Shelton LM; Seyfried TN
Int J Cancer; 2010 Jan; 126(1):65-72. PubMed ID: 19536778
[TBL] [Abstract][Full Text] [Related]
55. Prevention of lung cancer recurrence using cisplatin-loaded superhydrophobic nanofiber meshes.
Kaplan JA; Liu R; Freedman JD; Padera R; Schwartz J; Colson YL; Grinstaff MW
Biomaterials; 2016 Jan; 76():273-81. PubMed ID: 26547283
[TBL] [Abstract][Full Text] [Related]
56. Tumorigenic stem and progenitor cells: implications for the therapeutic index of anti-cancer agents.
Donnenberg VS; Landreneau RJ; Donnenberg AD
J Control Release; 2007 Oct; 122(3):385-91. PubMed ID: 17582641
[TBL] [Abstract][Full Text] [Related]
57. Cytoskeletal reorganization and cell death in mitoxantrone-treated lung cancer cells.
Pawlik A; Szczepanski MA; Klimaszewska-Wisniewska A; Gackowska L; Zuryn A; Grzanka A
Acta Histochem; 2016 Oct; 118(8):784-796. PubMed ID: 27817864
[TBL] [Abstract][Full Text] [Related]
58. Cholesterol depletion decreases adhesion of non-small cell lung cancer cells to E-selectin.
Mohammadalipour A; Showalter CA; Muturi HT; Farnoud AM; Najjar SM; Burdick MM
Am J Physiol Cell Physiol; 2023 Aug; 325(2):C471-C482. PubMed ID: 37399498
[TBL] [Abstract][Full Text] [Related]
59. Mitochondrial targeting overcomes ABCA1-dependent resistance of lung carcinoma to α-tocopheryl succinate.
Prochazka L; Koudelka S; Dong LF; Stursa J; Goodwin J; Neca J; Slavik J; Ciganek M; Masek J; Kluckova K; Nguyen M; Turanek J; Neuzil J
Apoptosis; 2013 Mar; 18(3):286-99. PubMed ID: 23299931
[TBL] [Abstract][Full Text] [Related]
60. Impact of host ageing on the metastatic phenotype.
Meehan B; Dombrovsky A; Lau K; Lai T; Magnus N; Montermini L; Rak J
Mech Ageing Dev; 2013 Mar; 134(3-4):118-29. PubMed ID: 23403123
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
